Loading stock data…
TMDX
$74.29+3.15 (+4.43%)
After Hours$74.61+0.32 (+0.43%)· Last close Jun 9
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
TransMedics Group, Inc. in the Healthcare sector is trading at $74.29. Wall Street consensus targets $116.78 (9 analysts), implying a +57.2% move over the next 12 months. The stock is currently near its 52-week low of $60.10, remaining 36.2% below its 200-day moving average. On fundamentals, Piotroski 7/9 indicates strong financial quality, Altman Z in the distress zone. Risk note: RSI 72 is overbought against a weak tape. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +57.2% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Overbought RSI 72 against a weak tape — risk of pullback
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$74.29
Potential Downside
0%
Whystock Fair Value$74.29
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus9 analysts
Buy
Mean target$116.78+57.2%
Range$75.00 – $142.00
Fundamentals
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company provides Organ Care System (OCS), a po...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
34.80%
Volume
Today's trading volume
1.22M
Recent News
Will Analyst Focus on TransMedics’ OCS Platform and Financial Metrics Change TransMedics Group’s (TMDX) Narrative?
In recent coverage, TransMedics Group’s Organ Care System (OCS) has been highlighted for its role in transforming organ transplant therapy by maintaining organs in near-physiological conditions, while analysts have pointed to solid revenue growth and strong return on equity as key strengths. An interesting angle for investors is how the OCS platform’s potential to extend organ viability may underpin a wider shift in transplant practices and healthcare infrastructure investment. Next, we’ll...
TransMedics (TMDX) Down 4.4% Since Last Earnings Report: Can It Rebound?
TransMedics (TMDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Reasons to Retain TransMedics Stock in Your Portfolio for Now
TMDX is advancing its OCS platform and transplant ecosystem, but margin pressure from expansion investments remains a key concern.
Assessing TransMedics Group (TMDX) Valuation After A Sharp One Year Share Price Decline
Stock performance context for TransMedics Group investors TransMedics Group (TMDX) has drawn attention after a period of weak share performance, with the stock down about 7% over the past day and about 50% over the past 3 months. That setback contrasts with the company’s current fundamentals, including reported revenue of US$635.89 million and net income of US$171.924 million. These figures give investors concrete financial data to weigh against the recent share price slide. See our latest...
TransMedics Group Inc (TMDX) Q1 2026 Earnings Call Highlights: Strong Revenue Growth Amid ...
TransMedics Group Inc (TMDX) reports a 21% revenue increase while navigating regulatory impacts and competitive pressures.